Explore our premium grade chemical products and specialized active pharmaceutical ingredients manufactured under international cGMP standards.
Understanding the molecular pharmacology, crystallization chemistry, and rigorous technical specifications governing commercial Sorafenib production.
Sorafenib (typically supplied as Sorafenib Tosylate, CAS 475207-59-1) is a potent, oral bi-aryl urea targeting multiple intracellular and cell-surface receptor tyrosine kinases. It acts as a dual-action inhibitor: target RAF kinases (C-RAF, BRAF, wild-type and mutant V600E) to inhibit tumor cell proliferation, while simultaneously targeting VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-β to suppress tumor angiogenesis.
The manufacturing process strictly regulates crystallization parameters to produce stable Form III / Form I polymorphs. Ensuring precise particle size distribution (D90 < 10 µm via micronization) and preventing crystal transition during storage is essential to guarantee consistent oral bio-absorption and bioequivalence matching reference listed drugs (RLD).
| Chemical Property / Standard Parameter | OEM Industry Standard Specification | Gentolex High-Purity Benchmark |
|---|---|---|
| IUPAC Name | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide | Conforms to USP/EP Reference Standards |
| CAS Number | 284461-73-0 (Free Base) / 475207-59-1 (Tosylate Salt) | Certified 475207-59-1 |
| Assay (HPLC, Anhydrous Basis) | 98.0% – 102.0% | ≥ 99.5% Purity |
| Individual Impurity | ≤ 0.15% | ≤ 0.05% (Strict Genotoxic Control) |
| Polymorphic Form | Stable Polymorph Form III / I | 100% Phase Pure (Verified by PXRD & DSC) |
| Residual Solvents (ICH Q3C) | Meets ICH Guidance Limits | Ultra-low ppm via Gas Chromatography (GC-MS) |
Analyzing key structural, economic, and technological drivers that establish China as the premier global manufacturing hub for Sorafenib APIs and Finished Dosage Forms (FDF).
China hosts complete vertical integration for key intermediates such as 4-chloro-3-(trifluoromethyl)phenyl isocyanate and 4-(4-aminophenoxy)picolinamide. Local raw material synthesis eliminates global supply chain bottlenecks, lowers intermediate sourcing costs by 30-40%, and ensures batch consistency.
Leading Chinese factories utilize micro-channel reaction systems and continuous flow synthesis for the hazardous nitration and condensation steps. This significantly boosts reaction yields, prevents side-reactions (genotoxic impurities), and minimizes environmental impact while optimizing thermal controls.
Chinese OEM 25 facilities operate under stringent cGMP guidelines (aligned with US FDA 21 CFR Part 211, EU GMP Annex 1, and NMPA standards). Full eCTD Drug Master Files (USDMF, CEP) are readily available to accelerate global market registration and license-out procedures.
Information Gain Insight: The shift towards China for OEM Sorafenib manufacturing is no longer driven solely by cost efficiency, but by superior process engineering, continuous flow technology adoption, fast scaling capability (from kilogram research lots to multi-ton commercial orders), and unmatched supply resilience.
Market expansion, patent expiration opportunities, and emerging multi-targeted therapy combinations in liver, kidney, and thyroid oncology fields.
With patent expirations across key jurisdictions, pharmaceutical companies across LATAM, Southeast Asia, the Middle East, and Africa are actively seeking reliable OEM 25 Sorafenib partners to launch affordable 200mg film-coated generic tablets to meet rising demand.
Clinical research continues to explore Sorafenib in combination with immune checkpoint inhibitors (PD-1/PD-L1 antibodies) and transarterial chemoembolization (TACE). These multi-modal protocols sustain steady long-term demand for high-grade bulk API.
Tailored oral drug delivery techniques and clinical application profiles for customized B2B pharma manufacturing.
Sorafenib remains a benchmark first-line systemic therapy for patients with unresectable hepatocellular carcinoma. OEM production ensures exact bioequivalence, uniform dissolution profiles (>85% within 30 min in SLS media), and optimal GI absorption.
For patients who have failed prior cytokine-based therapy, Sorafenib provides sustained progression-free survival. Manufacturing precision focuses on reducing polymorphic transformation during wet granulation and tableting processes.
Sorafenib is indicated for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid carcinoma. Customized OEM formulations support long shelf-life stability under tropical zones IVa and IVb.
From custom peptide and chemical API synthesis to FDF license-out, technical support, and turnkey laboratory configuration.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
Factory Construction & Infrastructure: An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Pharmaceutical Ingredients: Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
Procurement Service: For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
A multi-point evaluation guide for pharmaceutical sourcing directors, QA managers, and supply chain executives.
Ensure your chosen manufacturer provides comprehensive Open & Closed parts of Drug Master Files (DMF), ASMF, stability testing datasets (accelerated and long-term according to ICH Q1A), process validation reports, and elemental impurity assessments (ICH Q3D).
Sorafenib Tosylate exhibits moisture sensitivity that can lead to polymorphic transitions over long ocean transit. Procurement specs must require double polyethylene bag linings enclosed inside light-resistant aluminum foil outer bags placed in tamper-evident fiber drums.
Partnering with organizations like Gentolex Group—with established regional representative hubs in Mexico and South Africa—reduces shipping lead times, facilitates localized customs clearance, and ensures local technical support for regional drug registration.
Stay updated with our latest scientific breakthroughs, API manufacturing innovations, and peptide research developments.
Clear expert answers regarding Sorafenib API technical specifications, OEM capabilities, and procurement procedures.
Browse our additional specialized products, synthetic peptides, and active chemical ingredients.
